Atomic structure of progesterone complexed with its receptor

The physiological effects of progestins are mediated by the progesterone receptor, a member of the steroid/nuclear receptor superfamily. As progesterone is required for maintenance of pregnancy, its receptor has been a target for pharmaceuticals. Here we report the 1.8 Å crystal structure of a progesterone-bound ligand-binding domain of the human progesterone receptor. The nature of this structure explains the receptor's selective affinity for progestins and establishes a common mode of recognition of 3-oxy steroids by the cognate receptors. Although the overall fold of the progesterone receptor is similar to that found in related receptors, the progesterone receptor has a quite different mode of dimerization,. A hormone-induced stabilization of the carboxy-terminal secondary structure of the ligand-binding domain of the progesterone receptor accounts for the stereochemistry of this distinctive dimer, explains the receptor's characteristic pattern of ligand-dependent protease resistance and its loss of repression,, and indicates how the anti-progestin RU486 might work in birth control. The structure also indicates that the analogous 3-keto-steroid receptors may have a similar mechanism of action.

[1]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[2]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[3]  B. O’Malley,et al.  Dimerization of the chicken progesterone receptor in vitro can occur in the absence of hormone and DNA. , 1990, Molecular endocrinology.

[4]  D. F. Skafar.  Dimerization of the RU486-bound calf uterine progesterone receptor , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[6]  D. Edwards,et al.  Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor. , 1992, Biochemistry.

[7]  P. Chambon,et al.  Activation function 2 (AF‐2) of retinoic acid receptor and 9‐cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF‐2 activity. , 1994, The EMBO journal.

[8]  D. Edwards,et al.  Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.

[9]  D. F. Skafar.  Differential DNA binding by calf uterine estrogen and progesterone receptors results from differences in oligomeric states. , 1991, Biochemistry.

[10]  B. O’Malley,et al.  The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor , 1992, Cell.

[11]  E. Baulieu.  Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor , 1989 .

[12]  Role of the C terminus of the glucocorticoid receptor in hormone binding and agonist/antagonist discrimination. , 1996, Molecular endocrinology.

[13]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[14]  R. Fletterick,et al.  A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[16]  David S. Wishart,et al.  Constrained multiple sequence alignment using XALIGN , 1994, Comput. Appl. Biosci..

[17]  H. Beug,et al.  v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA , 1990, Cell.

[18]  T. H. van der Kwast,et al.  Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. , 1991, Molecular endocrinology.

[19]  H. Rochefort,et al.  Differential Interaction of Nuclear Receptors with the Putative Human Transcriptional Coactivator hTIF1* , 1997, The Journal of Biological Chemistry.

[20]  L. Klein-Hitpass,et al.  Activation of transcription by progesterone receptor involves derepression of activation functions by a cofactor. , 1997, Molecular endocrinology.

[21]  P. Chambon,et al.  A single amino acid that determines the sensitivity of progesterone receptors to RU486. , 1992, Science.

[22]  B. O’Malley,et al.  The extreme C terminus of progesterone receptor contains a transcriptional repressor domain that functions through a putative corepressor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Edwards,et al.  Progesterone receptor and the mechanism of action of progesterone antagonists , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  P. Chambon,et al.  Ligand-dependent interaction of nuclear receptors with potential transcriptional intermediary factors (mediators). , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[25]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[26]  M. Tanen,et al.  Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor. , 1997, Molecular Endocrinology.

[27]  R. Lanz,et al.  A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors. , 1994, Endocrinology.

[28]  D. Edwards,et al.  Hinge and amino-terminal sequences contribute to solution dimerization of human progesterone receptor. , 1997, Molecular endocrinology.